Network News

BioMed X Institute, in collaboration with the Government of Barbados and the European Commission, is launching BioMed X Barbados, a new research initiative focused on better treatment of cardiometabolic diseases in individuals of African descent. Heidelberg, Germany / Bridgetown, Barbados – February 20, 2025. BioMed X Institute is proud to announce a partnership with the […]

Extraordinary funding from the Chan Zuckerberg Initiative supports two large collaborative projects that will boost imaging technology development By Stephanie Alexander, EMBL Imaging Centre Research & Service Coordinator Developing advanced imaging technologies is critical to advancing life sciences research. It is especially important to explore the detailed structure and function of tissues, cells, and macromolecules […]

A combination of new laboratory technology and artificial intelligence is set to make the rapid and precise differentiation of subgroups of brain tumours widely available. An international research group led by Professor Dr. Dr. Felix Sahm from the Department of Neuropathology at Heidelberg University Hospital and the Heidelberg Faculty of Medicine at Heidelberg University is […]

Approval based on positive results from Phase III ATTRibute-CM study / Beyonttra™ is a near-complete (≥90%) stabilizer of transthyretin (TTR) minimizing amyloid formation / Phase III ATTRibute-CM study with Beyonttra™ has shown clear benefits on cardiovascular endpoints already starting as early as 3 months after treatment initiation. Berlin, February 11, 2025 – The European Commission has […]

The European vaccine development ecosystem has been strengthened over the last 16 years, thanks to the EVI-led TRANSVAC project, an ambitious initiative funded by the European Commission. Since its launch in 2009, TRANSVAC has established itself as a key player in advancing vaccine research, supporting over 160 vaccine projects while fostering innovation and collaboration in […]

Zwingenberg, Germany, 4 February 2025 – Akribion Therapeutics (“Akribion”), the early-stage biotech developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announces its exit from stealth and the completion of a Seed Financing round raising EUR 8 million to accelerate the development of novel therapeutics based on Akribion’s proprietary G-dase® E nucleases. The round […]

Uppsala, Sweden, 05 February 2025: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers, today announced the introduction of its Gyrolab® HEK293 HCP Type SN Kit Reagents and Gyrolab HEK293 HCP Type CL Kit Reagents. Developed with antibodies from BioGenes GmbH, a global leader in host cell protein (HCP) assay […]

The research of BioMed X team EDC – Extrachromosomal DNA in Cancer – has uncovered critical insights into the mechanisms driving extrachromosomal DNA (ecDNA) formation and maintenance, offering potential avenues for novel cancer therapies. Heidelberg, Germany, February 6, 2025. BioMed X, a German independent research institute, announces the successful completion of its oncology research project in partnership […]

Three institutions have joined our consortium as official Chemoproteomics and Spatial Mass Spectrometry (MS)-Based Omics partner sites, enhancing the services we can offer to the research community in the areas of target identification and validation. Phil Gribbon, Director General of EU-OPENSCREEN, emphasised: “The three new chemoproteomics sites joining the EU-OPENSCREEN partner network provide a significant boost […]